The FDA recently approved a form of ecstasy for large-scale clinical trials as a treatment for post-traumatic stress disorder, the New York Times reports.
According to the Times, the FDA has approved MDMA — a “pure” form of ecstasy, also commonly referred to as “molly” — for the third and final phase of human trials.
One study indicates that after three doses of MDMA, 56 percent of people suffering from PTSD reported a decrease in the severity of their symptoms — and follow-up exams indicated that the effects lasted for up to a year.
According to the New York Times, MDMA causes the brain to “release feelings of trust, love and well-being, while muting fear and negative emotional memories,” allowing those suffering with PTSD to focus on positive memories and thoughts.
While researchers are excited about the possibilities for treating PTSD, they are wary of potential abuses that a feel-good drug like ecstasy can cause.
“It’s a feel-good drug, and we know people are prone to abuse it,” Dr. Charles R. Marmar told the New York Times. “Prolonged use can lead to serious damage to the brain.”
If human trials continue to show improvement for those with PTSD, MDMA could be cleared for clinical use by 2021.
Alex Hider is a writer for the E.W. Scripps National Desk. Follow him on Twitter @alexhider.
The usual suspects top this year's list of the most frequently lost items in the Nevada desert at the annual Burning Man festival: 582…
Americans love eggnog, so we're taking a look at its history to see what makes it so special.
A New York City restaurant is serving up America's most expensive Thanksgiving dinner.
The U.S. Postal Service is running its "Letters from Santa" program, which means that your child can get a letter from ol' St.…
Video of a father in Tennessee who put on a tutu for his daughter's ballet class is going viral.
Facebook is apologizing to the family of the "boss of bosses" of Italy's Mafia for having removed messages of condolences that…